AbCellera Biologics Inc. — Operating Income by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/59a85c5c-d115-40ee-8f65-7162579bcba8/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-217.1M | 2025-01-01 – 2025-12-31 | evidence 0001703057-26-000012 |
| FY 2024 | $-314.8M | 2024-01-01 – 2024-12-31 | evidence 0001628280-25-008689 |
| FY 2023 | $-237.2M | 2023-01-01 – 2023-12-31 | evidence 0001703057-24-000019 |
| FY 2022 | $216.5M | 2022-01-01 – 2022-12-31 | evidence 0001564590-23-002128 |
| FY 2021 | $204.4M | 2021-01-01 – 2021-12-31 | evidence 0001564590-22-007077 |
| FY 2020 | $156.0M | 2020-01-01 – 2020-12-31 | evidence 0001564590-22-007077 |
| FY 2019 | $-4.1M | 2019-01-01 – 2019-12-31 | evidence 0001564590-22-007077 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).